IMPORTANCE OF APOPTOSIS MARKERS (MDM2, BCL-2 AND Bax) IN CONVENTIONAL RENAL CELL CARCINOMA
Keywords:Renal cell carcinoma, apoptosis
The goal of the current study was to analyze the expression of Bcl-2, MDM2 and Bax in benign and malignant renal tissue samples and assess their possible association with different clinical parameters. Prognostic significance of the markers in recurrence-free and cancer-specific survivals has also been evaluated. Activity of MDM2, Bcl-2 and Bax was evaluated in: 24 normal human kidney tissues resected from the patients of different ages (range: 21-80 years), and in 52 conventional RCC samples. Intensity of the markers’ expression was compared between the groups and correlation was analyzed with different clinical parameters.Activity of anti-apoptotic MDM2 and Bcl-2 was significantly elevated while activity of pro-apoptotic Bax was decreased in RCC as compared with normal kidney tissues. Bax expression was positively correlated with patient age. Significant association has been detected between the evaluated markers and cancer clinical parameters like: tumor stage, grade, lymph node and distant metastases. The markers’ activity was associates with the tumor morphological features, in particular: presence of tumor necrosis and microvascular invasion. Disease recurrence and 5-year patient survival were associated with the markers’ activity. Cox regression analyses have shown that tumor size, pathological stage and grade are the risk factors for disease recurrence and patient death.Expression of MDM2 and Bcl-2 is significantly up-regulated, while Bax is down-regulated in RCC as compared with normal kidney tissue. Intensity of the markers’ activities is associated with the tumor pathological and clinical parameters (stage, grade, lymph node and distant metastases, tumor recurrence and patient survival). Further studies with more patients and longer follow-up will uncover the clinical importance of the evaluated markers in RCC.
Kernion JB. Reexamination of current staging for renal cell carcinoma. J Urol 2005; 173:680.
Kallio JP, Hirvikoski P, Helin H, Luukkaala T, Tammela TL, Kellokumpu-Lehtinen P, Martikainen PM. Renal cell carcinoma MIB-1, Bax and Bcl-2 expression and prognosis. J Urol. 2004; 172: 2158-6.
Kontak JA, Campbell SC. Prognostic factors in renal cell carcinoma. Urol Clin North Am 2003; 30: 467-481.
Lam JS, Shvarts O, Leppert JT, et al. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005; 173:1853-1862.
Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 2005; 66 (S5): 1-9.
Morais C, Pat B, Gobe G, Johnson DW, Healy H. Pyrrolidine dithiocarbamate exerts anti-proliferative and pro- apoptotic effects in renal cell carcinoma cell lines. Nephrol Dial Transplant. 2006; 21: 3377-88.
Morais C, Healy H, Johnson DW, Gobe G. Inhibition of nuclear factor kappa B attenuates tumor progression in an animal model of renal cell carcinoma. Nephrol Dial Transplant. 2010; 25: 1462-74.
Noon AP, Polański R, El-Fert AY, et al. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy. BJU Int. 2012; 109: 1250-7.
Noon AP, Vlatković N, Polański R, et al. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets? Cancer 2010; 116: 780-90.
Oosterwijk E. Tumor markers for renal cell carcinoma. J Urol 2005; 173:2150-2155.
Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166:1611-1623.
Poulos CK, et al. Preoperative prediction of Gleason grade in radical prostatectomy specimens: the influence of different Gleason grades from multiple positive biopsy sites. Modern Pathology 2005; 18: 228–234.
Sakr WA, Scott ML. Potential pathologic markers for prostate chemoprevention studies. Urol Clin N Am 2004; 31: 227–235.
Shvarts O, Lam JS, Kim HL, Belldegrun AS. Staging of renal cell carcinoma: current concepts. BJU Int 2005; 95:8-13.
Terakawa T, Miyake H, Kusuda Y, Fujisawa M. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib. Urol Oncol. 2013; 31: 493-8.
Vatsyayan R, Singhal J, Nagaprashantha LD, Awasthi S, Singhal SS. Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma. Mol Carcinog. 2013; 52: 39-48.